Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis

被引：1
|
作者：
Wendling, Daniel [1 ]
Goupille, Philippe [2 ]
机构：
[1] Univ Franche Comte, CHRU Besancon, Serv Rhumatol, EA 4266, Besancon, France
[2] Univ Tours, CHRU Tours, Serv Rhumatol, EA 7501,GICC, Tours, France
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 12期
关键词：
ankylosing spondylitis; anti-IL-17; anti-TNF; axial spondyloarthritis; disease activity; treatment; ANKYLOSING-SPONDYLITIS;
D O I：
10.2217/imt-2020-0094
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：857 / 860
页数：4
相关论文
共 50 条
  • [21] Disease-modifying antirheumatic drugs
    Slack, S
    Furst, DE
    DRUGS OF TODAY, 1996, 32 (06) : 463 - 476
  • [22] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    SMITH, MD
    AHERN, MJ
    MEDICAL JOURNAL OF AUSTRALIA, 1992, 157 (11-12) : 797 - 801
  • [23] Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Hosseini, Roya
    Brown, Lawrence
    Fleming, Marc
    Rodriguez-Monguio, Rosa
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2161 - 2162
  • [24] Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma
    Calip, Gregory S.
    Patel, Pritesh R.
    Sweiss, Karen
    Wu, Zhaoju
    Zhou, Jifang
    Asfaw, Alemseged A.
    Adimadhyam, Sruthi
    Lee, Todd A.
    Chiu, Brian C-H
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (05) : 1300 - 1305
  • [25] Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis
    Li, Philip Hei
    Chan, Shirley Chiu Wai
    Lau, Chak Sing
    Seto, Mimi Tin Yan
    Chung, Ho Yin
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (01) : E63 - E68
  • [26] Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis: A review of the literature and discussion on current practice
    Webers, Casper
    Nikiphorou, Elena
    Boonen, Annelies
    Ramiro, Sofia
    JOINT BONE SPINE, 2023, 90 (01)
  • [27] Modern disease-modifying antirheumatic drugs
    Mueller-Ladner, U.
    Richter, K.
    Tarner, I. H.
    INTERNIST, 2015, 56 (03): : 307 - 314
  • [28] TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR
    Joanna, Kedra
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1147 - 1148
  • [29] Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
    Razak, Salmi Abdul
    Bakry, Mohd Makmor
    Said, Mohd Shahrir Mohamed
    Tan, Chai-Eng
    Redzuan, Adyani Md
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [30] Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases
    Fazaa, Alia
    Makhlouf, Yasmine
    Ben Ouhiba, Amad
    Miladi, Saoussen
    Sellami, Mariem
    Ouenniche, Kmar
    Souabni, Leila
    Kassab, Salma
    Chekili, Selma
    Zakraoui, Leith
    Ben Abdelghani, Kawther
    Laatar, Ahmed
    THERAPIE, 2021, 76 (05): : 467 - 474
12345